A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA

E. Mandelli; M. L. Vegna; G. Awisati; S. Amadori; A. Spadea; E. Cacciola; N. Cantore; A. De Laurenzi; C. De Rosa; G. Fioritoni; A. Gabbas; V. Liso; C. Malleo; E. Miraglia; M. Montillo; R. Perricone; A. Peta; F. Ricduti; M. C. Petti

doi:10.1007/BF01696218

A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA

E. Mandelli, M. L. Vegna, G. Awisati, S. Amadori, A. Spadea, E. Cacciola, N. Cantore, A. De Laurenzi, C. De Rosa, G. Fioritoni, A. Gabbas, V. Liso, C. Malleo, E. Miraglia, M. Montillo, R. Perricone, A. Peta, F. Ricduti, M. C. Petti

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.

Original language	English
Pages (from-to)	166-172
Number of pages	7
Journal	Annals of Hematology
Volume	64
Issue number	4
DOIs	https://doi.org/10.1007/BF01696218
Publication status	Published - Apr 1992

Keywords

Adult acute nonlymphocytic leukemia
Chemotherapy
Post-consolidation approaches

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/BF01696218

Cite this

Mandelli, E., Vegna, M. L., Awisati, G., Amadori, S., Spadea, A., Cacciola, E., Cantore, N., De Laurenzi, A., De Rosa, C., Fioritoni, G., Gabbas, A., Liso, V., Malleo, C., Miraglia, E., Montillo, M., Perricone, R., Peta, A., Ricduti, F., & Petti, M. C. (1992). A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. Annals of Hematology, 64(4), 166-172. https://doi.org/10.1007/BF01696218

Mandelli, E, Vegna, ML, Awisati, G, Amadori, S, Spadea, A, Cacciola, E, Cantore, N, De Laurenzi, A, De Rosa, C, Fioritoni, G, Gabbas, A, Liso, V, Malleo, C, Miraglia, E, Montillo, M, Perricone, R, Peta, A, Ricduti, F & Petti, MC 1992, 'A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA', Annals of Hematology, vol. 64, no. 4, pp. 166-172. https://doi.org/10.1007/BF01696218

@article{a922d257422b46ed9c161ddf2d60f125,

title = "A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA",

abstract = "The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.",

keywords = "Adult acute nonlymphocytic leukemia, Chemotherapy, Post-consolidation approaches",

author = "E. Mandelli and Vegna, {M. L.} and G. Awisati and S. Amadori and A. Spadea and E. Cacciola and N. Cantore and {De Laurenzi}, A. and {De Rosa}, C. and G. Fioritoni and A. Gabbas and V. Liso and C. Malleo and E. Miraglia and M. Montillo and R. Perricone and A. Peta and F. Ricduti and Petti, {M. C.}",

year = "1992",

month = apr,

doi = "10.1007/BF01696218",

language = "English",

volume = "64",

pages = "166--172",

journal = "Revue d'hématologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia

T2 - a report of the Italian Cooperative Group GIMEMA

AU - Mandelli, E.

AU - Vegna, M. L.

AU - Awisati, G.

AU - Amadori, S.

AU - Spadea, A.

AU - Cacciola, E.

AU - Cantore, N.

AU - De Laurenzi, A.

AU - De Rosa, C.

AU - Fioritoni, G.

AU - Gabbas, A.

AU - Liso, V.

AU - Malleo, C.

AU - Miraglia, E.

AU - Montillo, M.

AU - Perricone, R.

AU - Peta, A.

AU - Ricduti, F.

AU - Petti, M. C.

PY - 1992/4

Y1 - 1992/4

N2 - The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.

AB - The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.

KW - Adult acute nonlymphocytic leukemia

KW - Chemotherapy

KW - Post-consolidation approaches

UR - http://www.scopus.com/inward/record.url?scp=0026593794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593794&partnerID=8YFLogxK

U2 - 10.1007/BF01696218

DO - 10.1007/BF01696218

M3 - Article

C2 - 1581404

AN - SCOPUS:0026593794

VL - 64

SP - 166

EP - 172

JO - Revue d'hématologie

JF - Revue d'hématologie

SN - 0939-5555

IS - 4

ER -

A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this